Literature DB >> 21464787

Myxofibrosarcoma of the orbit: case report and review of literature.

Julien Gire1, Nicolas Weinbreck, François Labrousse, Danièle Denis, Jean-Paul Adenis, Pierre-Yves Robert.   

Abstract

A 17-year-old man was referred with a 6-month history of painless left inferior eyelid edema. Ophthalmic examination was normal except for the presence of a reddish conjunctiva in the left eye medial canthus. MRI demonstrated a 20-mm well-defined extraconical mass between the medial and inferior rectus muscle without destruction of the medial orbital wall. A low-grade myxofibrosarcoma was diagnosed on orbital biopsy. The tumor was locally excised, but the patient categorically refused left exenteration or conformal radiotherapy. He accepted to have annual clinical and radiologic checkup. To date, 2 years later, he has been followed up with no evidence of tumor recurrence. Orbital localization of myxofibrosarcoma is extremely rare, with only 2 cases reported in the literature. The differential diagnosis could be difficult: here, a fibromyxoid sarcoma and a myxoid variant of dedifferentiated liposarcoma have been especially discussed in terms of their histopathologic features. Risk of metastasis is related to the tumor grade. Management of these tumors associates surgery with orbital exenteration or globe-sparing approaches and postsurgical adjuvant radiation therapy.

Entities:  

Mesh:

Year:  2012        PMID: 21464787     DOI: 10.1097/IOP.0b013e318211040d

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

Review 1.  Giant myxofibrosarcoma of the orbit: a rare case and a review of the literature.

Authors:  Rachna Meel; Gautam Lokdarshi; Seema Kashyap; Sanjay Sharma
Journal:  BMJ Case Rep       Date:  2016-06-13

Review 2.  Multiple recurrent myxofibrosarcoma of the orbit: case report and review of the literature.

Authors:  Baixue Du; Xin He; Yujiao Wang; Weimin He
Journal:  BMC Ophthalmol       Date:  2020-07-06       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.